Martin Stork, Eva Ondrouskova, Michaela Bohunova, Ivanna Boichuk, Dominik Fric, Zdenek Adam, Marta Krejci, Viera Sandecka, Zdenka Knechtova, Lenka Radova, Zuzana Jelinkova, Tatana Adlerova, Milan Krticka, Vladimir Nekuda, Marek Borsky, Sabina Sevcikova, Marie Jarosova, Ludek Pour
{"title":"Del(1p32)是多发性骨髓瘤骨外疾病患者的早期高危因素。","authors":"Martin Stork, Eva Ondrouskova, Michaela Bohunova, Ivanna Boichuk, Dominik Fric, Zdenek Adam, Marta Krejci, Viera Sandecka, Zdenka Knechtova, Lenka Radova, Zuzana Jelinkova, Tatana Adlerova, Milan Krticka, Vladimir Nekuda, Marek Borsky, Sabina Sevcikova, Marie Jarosova, Ludek Pour","doi":"10.1038/s41408-024-01131-6","DOIUrl":null,"url":null,"abstract":"","PeriodicalId":8989,"journal":{"name":"Blood Cancer Journal","volume":"14 1","pages":"146"},"PeriodicalIF":12.9000,"publicationDate":"2024-08-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11347579/pdf/","citationCount":"0","resultStr":"{\"title\":\"Del(1p32) is an early and high-risk event in multiple myeloma patients with extraosseous disease.\",\"authors\":\"Martin Stork, Eva Ondrouskova, Michaela Bohunova, Ivanna Boichuk, Dominik Fric, Zdenek Adam, Marta Krejci, Viera Sandecka, Zdenka Knechtova, Lenka Radova, Zuzana Jelinkova, Tatana Adlerova, Milan Krticka, Vladimir Nekuda, Marek Borsky, Sabina Sevcikova, Marie Jarosova, Ludek Pour\",\"doi\":\"10.1038/s41408-024-01131-6\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"\",\"PeriodicalId\":8989,\"journal\":{\"name\":\"Blood Cancer Journal\",\"volume\":\"14 1\",\"pages\":\"146\"},\"PeriodicalIF\":12.9000,\"publicationDate\":\"2024-08-26\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11347579/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Blood Cancer Journal\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1038/s41408-024-01131-6\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"HEMATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Blood Cancer Journal","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1038/s41408-024-01131-6","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"HEMATOLOGY","Score":null,"Total":0}
期刊介绍:
Blood Cancer Journal is dedicated to publishing high-quality articles related to hematologic malignancies and related disorders. The journal welcomes submissions of original research, reviews, guidelines, and letters that are deemed to have a significant impact in the field. While the journal covers a wide range of topics, it particularly focuses on areas such as:
Preclinical studies of new compounds, especially those that provide mechanistic insights
Clinical trials and observations
Reviews related to new drugs and current management of hematologic malignancies
Novel observations related to new mutations, molecular pathways, and tumor genomics
Blood Cancer Journal offers a forum for expedited publication of novel observations regarding new mutations or altered pathways.